Sogen Data · Datasets · 数据专题
膀胱癌复发轴数据集锦
单细胞 · bulk 转录组
本专题承自 Sogen Data 数据整理体系,逐条人工复核,附研究设计、样本量、平台与 GEO/PubMed 直达链接。
人源单细胞
Human · Single-cell
-
01 GSE269877 对非肌层浸润性膀胱癌(NMIBC)患者治疗前后的肿瘤样本进行单细胞RNA测序,比较BCG naive与BCG recurrent样本的免疫景观,同时分析正常输尿管样本作为对照。
设计对非肌层浸润性膀胱癌(NMIBC)患者治疗前后的肿瘤样本进行单细胞RNA测序,比较BCG naive与BCG recurrent样本的免疫景观,同时分析正常输尿管样本作为对照。
摘要Bacillus Calmette-Guérin (BCG) is the mainstay of treatment for intermediate- and high-risk non-muscle invasive bladder cancer (NMIBC), yet recurrence rates remain high. To improve the efficacy of BCG, a better understanding of the immune landscape underlying BCG resistance is critical. Here, we performed single-cell RNA-sequencing (scRNA-seq) and whole-exome sequencing on tumors from NMIBC patients before and after BCG treatment. Our analysis revealed a marked increase in CD6/ALCAM interactions between T cells and urothelial cells in BCG recurrent tumors. CD6-high T cells were enriched in recurrent tumors and exhibited downregulation of activation-related genes, indicative of functional impairment. These observations were supported by analysis of an independent BCG-treated NMIBC cohort, in which CD6/ALCAM signaling was correlated with shorter recurrence-free survival (p = 0.00059). Our findings reveal a previously unrecognized association between CD6/ALCAM signaling and BCG resistance in NMIBC patients and highlight this pathway as a potential therapeutic target to enhance response to BCG.
-
02 GSE270296 对9例膀胱癌患者的单核RNA测序样本进行分析,其中8例接受BCG治疗,3例出现疾病进展(progression: Y),其余为非进展样本(progression: N)。检测方式为单核RNA测序,比较BCG治疗组与未治疗组、进展样本与非进展样本的转录特征差异。
设计对9例膀胱癌患者的单核RNA测序样本进行分析,其中8例接受BCG治疗,3例出现疾病进展(progression: Y),其余为非进展样本(progression: N)。检测方式为单核RNA测序,比较BCG治疗组与未治疗组、进展样本与非进展样本的转录特征差异。
摘要In this study, we aimed to characterize cellular subtypes and cognate genetic markers using single nuclear RNA sequencing on 8 NMIBC samples treated with BCG, including 3 cases exhibited disease progression.
-
03 GSE277524 对多灶性膀胱癌患者的原发和复发肿瘤病变进行单细胞RNA测序,分析两者间的细胞异质性及微环境内细胞间通讯差异。
设计对多灶性膀胱癌患者的原发和复发肿瘤病变进行单细胞RNA测序,分析两者间的细胞异质性及微环境内细胞间通讯差异。
摘要Bladder carcinoma (BLCA) is characterized by a high rate of post-surgery relapse and multifocality, with multifocal tumors carrying a 40% higher risk of recurrence compared to single tumors. Recurrence is a major contributor to bladder cancer-specific mortality. However, understanding interregional or intraregional malignant heterogeneity and cellular communication within the primary and recurrence tumor microenvironment (TME) remains a significant challenge. Here, we employed single-cell RNA sequencing (scRNA-seq) to analyze separate tumor lesions from five multifocal bladder cancer patients (comprising three primary tumors and two recurrence tumors).
-
04 GSE190888 对三名患者来源的膀胱癌样本(原发性高分级、复发性低分级)及一名患者的glandular cystitis样本进行单细胞RNA测序,比较不同疾病状态下的转录组差异。
设计对三名患者来源的膀胱癌样本(原发性高分级、复发性低分级)及一名患者的glandular cystitis样本进行单细胞RNA测序,比较不同疾病状态下的转录组差异。
摘要To comprehensively understand the biological significance behind different grades of bladder cancer, we screened samples of different grades of bladder cancer and glandular cystitis from three patients for single-cell sequencing. In this study, We found that N-Glycan biosynthesis pathway was activated in high-grade bladder cancer while TNF-related pathway was activated in cystitis glandularis. More importantly, We discovered that N-Glycan biosynthesis is a potential target by cell assay and inhibition of this pathway may contribute to the treatment of bladder cancer.
人源bulk 转录组
Human · Bulk RNA-seq
-
01 GSE32894 对308例尿路上皮癌样本的总RNA进行基因表达分析,通过逐步划分和自举方法定义七个分子亚型,并在三个独立数据集中验证结果。研究对象为人类尿路上皮癌样本,检测方式为Illumina HumanHT-12 V3.0表达芯片,主要比较不同分子亚型间的基因表达差异。
设计对308例尿路上皮癌样本的总RNA进行基因表达分析,通过逐步划分和自举方法定义七个分子亚型,并在三个独立数据集中验证结果。研究对象为人类尿路上皮癌样本,检测方式为Illumina HumanHT-12 V3.0表达芯片,主要比较不同分子亚型间的基因表达差异。
摘要Even though urothelial cancer (UC) is the fourth common tumor type among males, progress in treatment development has been deficient. Pathological assessment provides the urologists with only a broad classification, complicated by frequent disagreement among pathologist and the co-existence of different grading systems. Consequently, there is a great need for an objective, reproducible and biologically relevant classification system to make treatment more efficient. In the present investigation we present a molecular taxonomy for UC stratification based on integrated genomics. We used gene expression profiles from 308 UC to define seven molecular subtypes using step-by-step partitions and a bootstrap approach. Results were validated in three independent and publically available data sets. The subtypes differ significantly with respect to expression of cell cycle genes, of receptor tyrosine kinases particularity FGFR3, ERBB2 (HER2), and EGFR, of an FGFR3 associated gene expression signature, of cytokaratins, and of cell adhesion genes. The subtypes also differ significantly with respect to FGFR3, PIK3CA, and TP53 mutations. The expression of key proteins was validated by IHC on TMA. A further inspection indicated that the subtypes could be reduced to four major types of UC; Urobasal/D-driven, Genomically unstable/E-driven, Evolved urobasal, and Basal/SCC like, with characteristic and highly divergent molecular phenotypes. We show that the molecular subtypes cut across pathological classification and that tumors classified as one subtype maintain their characteristic molecular phenotype irrespective of pathological stage and grade. Available data from the Drugbank database and the Cochrane central registry of controlled trials indicate that susceptibility to specific drugs is more likely to be associated with the molecular stratification than with pathological classification. The presented molecular taxonomy stratifies UC into subtypes with distinct molecular phenotypes and biological properties. We anticipate that the molecular taxonomy will be a useful tool in future clinical investigations.
-
02 GSE128959 对膀胱癌复发患者进行纵向研究,采集膀胱组织样本进行基因表达分析,比较不同肿瘤阶段和分子亚型的基因表达特征。
设计对膀胱癌复发患者进行纵向研究,采集膀胱组织样本进行基因表达分析,比较不同肿瘤阶段和分子亚型的基因表达特征。
摘要It is unclear how urothelial carcinoma of the urinary bladder change, genetically and phenotypically, as patients progress from recurrent non muscle-invasive (NMI) to muscle-invasive (MI) disease or disease that require radical cystectomy. This data set contains gene expression data from 200 samples in a longitudinal study of such patients. Overlap with previously GEO-published cohorts from our lab is described in the metadata.
-
03 GSE222073 对膀胱癌复发的bulk RNA数据进行回顾性队列研究,分析转移部位与化疗反应。研究对象为接受不同化疗方案的肌层浸润性膀胱癌患者,包括新辅助化疗、辅助化疗、姑息性化疗或少于2个周期新辅助化疗的患者。样本来源为FFPE组织,采用SensationPlus FFPE Amplification and WT labeling kit进行标记,按labeling batch分组。检测方式为基于GPL32998平台的基因表达分析,数据经过RNA标准化、ComBat批效应校正及按基因符号中位数合并。主要比较不同化疗类型与转移部位的关联。
设计对膀胱癌复发的bulk RNA数据进行回顾性队列研究,分析转移部位与化疗反应。研究对象为接受不同化疗方案的肌层浸润性膀胱癌患者,包括新辅助化疗、辅助化疗、姑息性化疗或少于2个周期新辅助化疗的患者。样本来源为FFPE组织,采用SensationPlus FFPE Amplification and WT labeling kit进行标记,按labeling batch分组。检测方式为基于GPL32998平台的基因表达分析,数据经过RNA标准化、ComBat批效应校正及按基因符号中位数合并。主要比较不同化疗类型与转移部位的关联。
摘要This series contains the gene expression data from urothelial bladder cancer samples from Swedish patients that were used to analyze metastatic sites. Included patients have a recurrence or distant metastasis before or after treatment with chemotherapy. Patients with only lymph-node metastases are not included. A previous series (GSE169455) contains data from all patients that recieved two or more cycles of neoadjuvant chemotherapy with curative intent. Patients in that series that developed distant recurrence are re-analyzed here. A few samples from a previous cystectomy series (GSE83586) are also included as re-analysis. In addition, the current series contains data from patients treated with palliative first-line chemotherapy, curative adjuvant chemotherapy, or < 2 cycles of neoadjuvant chemotherapy. Raw data should be adjusted in data processing for batch variables: Labeling batch and Labeling kit.
-
04 GSE120736 对来自25名患者的118例原发性膀胱癌样本和27例复发性膀胱肿瘤组织进行基因表达分析,采用bulk RNA测序技术,比较原发性与复发性样本的分子特征。
设计对来自25名患者的118例原发性膀胱癌样本和27例复发性膀胱肿瘤组织进行基因表达分析,采用bulk RNA测序技术,比较原发性与复发性样本的分子特征。
摘要Previous studies successfully revealed molecular characteristics of bladder cancers, dealing with non-muscle invasive bladder cancer and muscle invasive bladder cancer, separately. At the molecular level, however, there is a great need to aggregate these subtypes, which may share biological characteristics. This study aimed to identify distinct molecular subtypes of BC and the clinical and/or biological characteristics of each subtype. We used seven gene expression data sets for bladder cancer, which included data from 118 primary bladder cancer samples and 27 recurrent bladder tumor tissues from the Yonsei University Severance Hospital. Hierarchical clustering revealed four molecular subtypes of BC with different clinical outcomes: class 1 with low-grade NMIBC and the best prognosis; class 2 characterized by active FGFR3 and inhibited immune response pathways; class 3 with high-grade NMIBC and the worst progression-free survival; and class 4 mainly comprised of MIBC along with EMT activation. By applying the classifier based on these characteristics, we stratified all BC samples into newly identified molecular subtypes. When comparing previously reported subtypes, our subtypes well agreed with their molecular characteristics regardless of breast cancer-based biology, and showed a strong prognostic relevance in class 3. Integrative analysis of mutation and gene expression suggested that class 3 may have the potential benefit from anti-PD-L1 immunotherapy. Our classifier, constructed by NMIBC and MIBC integration, successfully stratified BC patients into distinct subtypes with different clinical outcomes and a possible treatment option.
-
05 GSE154261 对 T1 非肌层浸润性膀胱癌患者进行转录组测序,通过无监督聚类识别出五种共识亚型,并在第二队列中验证单样本亚型分类器。研究对象为 T1 高级别非肌层浸润性膀胱癌组织,采用 RNA-Seq 技术检测总 RNA 表达,主要比较不同亚型的转录特征差异。
设计对 T1 非肌层浸润性膀胱癌患者进行转录组测序,通过无监督聚类识别出五种共识亚型,并在第二队列中验证单样本亚型分类器。研究对象为 T1 高级别非肌层浸润性膀胱癌组织,采用 RNA-Seq 技术检测总 RNA 表达,主要比较不同亚型的转录特征差异。
摘要Stage T1 bladder cancers have the highest progression and recurrence rates of all non-muscle invasive bladder tumors. T1 tumors are heterogeneous; while most T1 patients are treated with BCG, many will progress and die from bladder cancer, and particularly aggressive tumors could be treated by early cystectomy. To better understand the molecular heterogeneity of T1 cancers, we performed transcriptome profiling and unsupervised clustering, identifying five consensus subtypes of T1 tumors treated with reTUR, induction and maintenance BCG. The T1-LumGU subtype was associated with CIS (6/13, 46% of all CIS), had high E2F1 and EZH2 expression, and enriched E2F target and G2M checkpoint Hallmarks. T1-Inflam was inflamed and infiltrated with immune cells. While most T1 tumors were classified as luminal papillary, the T1-TLum subtype had the highest median Luminal Papillary score and FGFR3 expression, no recurrence events, and the fewest copy number gains. T1-Myc and T1-Early subtypes had the most recurrences (14/30 within 24 months), highest median MYC expression, and, when combined, had significantly worse recurrence-free survival than the other three subtypes. T1-Early had 5 (38%) recurrences within the first 6 months of BCG, and repressed IFN-alpha and IFN-gamma Hallmarks and inflammation. We developed a single-patient T1 classifier and validated our subtype biology in a second cohort of T1 tumors. Future research will be necessary to validate the proposed T1 subtypes and to determine if therapies can be individualized for each subtype.
-
06 GSE294705 本研究基于 94 名非肌层浸润性膀胱癌(NMIBC)患者的转录组数据,旨在构建高频率复发指数(HfRI)以预测 NMIBC 多次复发并指导个性化治疗策略。研究使用 RNA 测序技术分析患者组织样本,根据是否发生 >=2 次复发分为不同组别,通过比较基因表达差异来识别与高频率复发相关的基因并构建预测模型。
设计本研究基于 94 名非肌层浸润性膀胱癌(NMIBC)患者的转录组数据,旨在构建高频率复发指数(HfRI)以预测 NMIBC 多次复发并指导个性化治疗策略。研究使用 RNA 测序技术分析患者组织样本,根据是否发生 >=2 次复发分为不同组别,通过比较基因表达差异来识别与高频率复发相关的基因并构建预测模型。
摘要Non-muscle invasive bladder cancer (NMIBC) has a recurrence rate of more than 50% after transurethral resection (TUR) and Calmette-Guérin (BCG) treatment. This study aimed to develop a high-frequency recurrence index (HfRI) to predict multiple recurrences in NMIBC patients and guide personalized treatment strategies. In this study, we analyzed transcriptome data (Discovery cohort) of 45 high-risk NMIBC patients who received intravesical BCG treatment, including patients with >=2 recurrences, to identify genes significantly associated with high-frequency recurrence and construct a signature. In addition, we validated the predictive performance using transcriptome data of 94 patients (Validation cohort).
-
07 GSE31684 本研究使用来自 93 名接受根治性膀胱切除术的膀胱癌患者的微阵列数据,分析与临床和预后变量相关的基因表达模式。
设计本研究使用来自 93 名接受根治性膀胱切除术的膀胱癌患者的微阵列数据,分析与临床和预后变量相关的基因表达模式。
摘要Urothelial carcinoma of the bladder is characterized by significant variability in clinical outcomes depending on stage and grade. The addition of molecular information may improve our understanding of such heterogeneity and enhance prognostic prediction. The purpose of this study was to validate and improve published prognostic signatures for high-risk bladder cancer.
-
08 GSE185264 对非肌层浸润性膀胱癌(NMIBC)样本进行NanoString nCounter平台的RNA表达分析,比较炎症肿瘤微环境特征与分子亚型对BCG免疫治疗后复发率的影响。研究对象为来自UNC和MSK两个独立队列的78例NMIBC组织样本,按免疫状态(high/low/medium)和BCG治疗状态(Treated.BCG/Observation)分组,检测总RNA表达水平,分析炎症特征与分子亚型对复发的关联性。
设计对非肌层浸润性膀胱癌(NMIBC)样本进行NanoString nCounter平台的RNA表达分析,比较炎症肿瘤微环境特征与分子亚型对BCG免疫治疗后复发率的影响。研究对象为来自UNC和MSK两个独立队列的78例NMIBC组织样本,按免疫状态(high/low/medium)和BCG治疗状态(Treated.BCG/Observation)分组,检测总RNA表达水平,分析炎症特征与分子亚型对复发的关联性。
摘要Improved risk stratification and predictive biomarkers of treatment response are needed for non–muscle-invasive bladder cancer (NMIBC). Here we assessed the clinical utility of targeted RNA and DNA molecular profiling in NMIBC. We performed RNA-based profiling by NanoString nCounter on non–muscle-invasive bladder cancer (NMIBC) clinical specimens and found that a novel expression signature of an inflamed tumor microenvironment (TME), but not molecular subtyping, was associated with improved recurrence-free survival after bacillus Calmette-Guérin (BCG) immunotherapy. We further demonstrated that immune checkpoint gene expression was not associated with higher recurrence rates after BCG.
-
09 GSE199618 对膀胱癌原发肿瘤、治疗后和复发肿瘤样本进行RNA-Seq测序,比较BCG治疗前后不同疾病状态及HLA状态的差异。研究对象包括HLA+和HLA-的膀胱癌细胞系5637、RT4、UMUC3,以及FFPE来源的膀胱组织样本。样本分为治疗前(Pre-BCG)和治疗后(Post-BCG)两组,其中复发肿瘤样本包含P26、P27、P22、P33、P14、P12、P25、P17、P31、P19、P18、P30、P28、P16、P12r、P22r、P25r、P26r、P27r、P31r、P33r、P14r、P17r、P19r、P28r、P30r、P18r、P30r、P12r、P22r、P25r、P26r、P27r、P31r、P33r、P14r、P17r、P19r、P28r、P30r、P18r等。检测方式为RNA-Seq,同时采用NanoString nSolver平台进行表达分析。
设计对膀胱癌原发肿瘤、治疗后和复发肿瘤样本进行RNA-Seq测序,比较BCG治疗前后不同疾病状态及HLA状态的差异。研究对象包括HLA+和HLA-的膀胱癌细胞系5637、RT4、UMUC3,以及FFPE来源的膀胱组织样本。样本分为治疗前(Pre-BCG)和治疗后(Post-BCG)两组,其中复发肿瘤样本包含P26、P27、P22、P33、P14、P12、P25、P17、P31、P19、P18、P30、P28、P16、P12r、P22r、P25r、P26r、P27r、P31r、P33r、P14r、P17r、P19r、P28r、P30r、P18r、P30r、P12r、P22r、P25r、P26r、P27r、P31r、P33r、P14r、P17r、P19r、P28r、P30r、P18r等。检测方式为RNA-Seq,同时采用NanoString nSolver平台进行表达分析。
摘要This SuperSeries is composed of the SubSeries listed below.
-
10 GSE224248 对非肌层浸润性膀胱癌(NMIBC)患者的原发性膀胱肿瘤样本进行总RNA提取,采用RNA-Seq技术分析基因表达,比较进展(progression: yes)与未进展(progression: no)组的基因表达差异,以开发预测疾病进展的预后指数。
设计对非肌层浸润性膀胱癌(NMIBC)患者的原发性膀胱肿瘤样本进行总RNA提取,采用RNA-Seq技术分析基因表达,比较进展(progression: yes)与未进展(progression: no)组的基因表达差异,以开发预测疾病进展的预后指数。
摘要Although recent advances in high-throughput technology and data-driven approach have provided many insights into non-muscle invasive bladder cancer (NMIBC), previous studies are still limited in their ability to predict the clinical behavior of NMIBC including response to intravesical therapy. We aim to develop a prognostic index (PI) consisting of a small gene group that predicts the NMIBC progression and response to intravesical bacillus calmette-guérin (BCG) therapy. We analyzed progression-associated genes using Cox regression analysis and validated their predictive values using a fully connected neural network (FNN) algorithm. By applying a pathway enrichment analysis to these genes, a PI system consisting of small core genes for NMIBC progression was developed. Gene expression profiling in NMIBC patients identified a prognostic gene set for predicting NMIBC progression in multiple patient cohorts. Pathway enrichment analysis revealed a 23-gene signature. We incorporated these genes into the PI system, which was a significant prognostic indicator of NMIBC progression. The PI system was shown to be an independent risk factor by a multivariate analysis and subset stratification according to stage and grade. The subset analysis also revealed that the PI system could identify patients who would benefit from BCG immunotherapy. The 23-gene-based PI represents a promising diagnostic tool for identifying high-risk NMIBC patients who would display different clinical behaviors and response to BCG immunotherapy.
-
11 GSE146870 对膀胱癌复发的尿路上皮癌样本进行总 RNA 测序,采集来自不同患者的新鲜冷冻切除样本,按患者 ID 和肿瘤复发时间点分层,采用 Illumina HumanHT-12 V3.0/V4.0 芯片平台检测,比较同一患者不同时间点肿瘤样本的基因组改变与分子亚型特征。
设计对膀胱癌复发的尿路上皮癌样本进行总 RNA 测序,采集来自不同患者的新鲜冷冻切除样本,按患者 ID 和肿瘤复发时间点分层,采用 Illumina HumanHT-12 V3.0/V4.0 芯片平台检测,比较同一患者不同时间点肿瘤样本的基因组改变与分子亚型特征。
摘要We made use of the fact that patients with non-muscle invasive tumors show frequent local recurrences and multiple tumors to study re-initiation of tumor growth from the same urothelium. By extensive genomic analyses we show that tumors from the same patient are clonal. We show that gross genomic chromosomal aberrations may appear abruptly and disappear with no transitional stages being observed. By analysis of incompatible changes i.e., genomic alterations that cannot be reversed, we show that almost all tumors from a single patient show such changes, thus the tumors cannot have originated from each other. As recurrent tumors share both genomic alterations and driver gene mutations, these must have been present in the histologically normal urothelium in periods with no tumor growth. We present a model that includes a growing and genomically evolving field of urothelial cells that occasionally, and locally, produce bursts of cellular growth leading to overt tumors. This gene expression data was used to check the molecular subtypes based on Lund taxonomy (LundTax) in the recurring urothelial carcinomas.
-
12 GSE163899 对非肌层浸润性膀胱癌(NMIBC)患者原发性膀胱肿瘤组织进行RNA-seq测序,将32例样本按术后疾病事件分为三组:非复发组(n=15)、复发组(n=9)和进展组(n=8)。总RNA采用RNeasy Mini Kit提取,经琼脂糖凝胶电泳、溴化乙锭染色及紫外灯检测确认质量。测序库使用TruSeq RNA Sample Preparation kit v2制备,包含mRNA纯化、cDNA合成、接头连接及PCR扩增步骤。最终在HiSeq 2500平台完成配对末端测序(2×150 bp),比较三组样本的转录组差异。
设计对非肌层浸润性膀胱癌(NMIBC)患者原发性膀胱肿瘤组织进行RNA-seq测序,将32例样本按术后疾病事件分为三组:非复发组(n=15)、复发组(n=9)和进展组(n=8)。总RNA采用RNeasy Mini Kit提取,经琼脂糖凝胶电泳、溴化乙锭染色及紫外灯检测确认质量。测序库使用TruSeq RNA Sample Preparation kit v2制备,包含mRNA纯化、cDNA合成、接头连接及PCR扩增步骤。最终在HiSeq 2500平台完成配对末端测序(2×150 bp),比较三组样本的转录组差异。
摘要Non-muscle-invasive bladder cancer (NMIBC) is clinically heterogeneous, and many NMIBC patients fail to respond to treatment and frequently experience disease relapse. We aim to identify a prognostic and predictive signature of the NMIBC heterogeneity. We constructed a transcriptomic data set by RNA-seq experiments from an independent NMIBC patient cohort (n=32). This cohort contains the patients stratified into three prognostic subgroups: Group 1 (patients with non-relapse; n=15), Group 2 (patients experiencing recurrence, n=9), and Group 3 (patients experiencing progression; n=8).
-
13 GSE88 将31例人类浅表膀胱肿瘤(Ta gr2)的总RNA进行表达谱分析,比较非复发与复发肿瘤的表达模式差异。
-
14 GSE199471 对高风险非肌层浸润性膀胱癌患者接受BCG治疗前后的膀胱肿瘤组织进行RNA-seq分析,比较治疗后HLA-I表达丢失与未丢失的两种肿瘤微环境特征。研究对象为接受BCG治疗的膀胱癌患者,材料包括治疗前原发肿瘤、治疗后复发肿瘤及相应对照样本,检测方式为RNA-Seq,主要比较HLA-I丢失型肿瘤(免疫沙漠微环境,富含髓系免疫抑制细胞)与HLA-I保持型肿瘤(Th1型免疫逃逸,高表达抑制性检查点和耗竭标志物)的基因表达差异。
设计对高风险非肌层浸润性膀胱癌患者接受BCG治疗前后的膀胱肿瘤组织进行RNA-seq分析,比较治疗后HLA-I表达丢失与未丢失的两种肿瘤微环境特征。研究对象为接受BCG治疗的膀胱癌患者,材料包括治疗前原发肿瘤、治疗后复发肿瘤及相应对照样本,检测方式为RNA-Seq,主要比较HLA-I丢失型肿瘤(免疫沙漠微环境,富含髓系免疫抑制细胞)与HLA-I保持型肿瘤(Th1型免疫逃逸,高表达抑制性检查点和耗竭标志物)的基因表达差异。
摘要Patients with high-risk non-muscle-invasive bladder carcinoma (NMIBC) frequently relapse after standard BCG immunotherapy and have a dismal outcome after progression to muscle-invasive bladder carcinoma (MIBC). Although BCG induces potent inflammatory responses upon intravesical instillations, the mechanisms of tumor resistance to such immunotherapy remain elusive. We performed a longitudinal immune profiling of a cohort of MIBC pre- and post BCG therapy with gene and protein expression analysis to establish correlations with 5 year clinical follow up. Here, we demonstrate two distinct patterns of BCG-induced immunosubversion, which include acquired immune resistance and tumor-cell intrinsic resistance. Firstly, intracellular BCG infection of a subset of urothelial carcinoma cells downregulated HLA-I expression and induced epithelial to mesenchymal transition (EMT) characteristics. BCG treated tumors exhibiting such HLA class I loss displayed an immune desert tumor microenvironment dominated by myeloid immunosuppressive cells. Such patients presented with early cancer relapses and a bad outcome. Conversely, BCG-treated tumors which did not lose HLA class I antigens at relapse displayed an immune escape mechanism dominated by a Th1 pattern with high expression of inhibitory checkpoints and exhaustion markers. Such patients had a favorable outcome upon second surgery. We surmise that HLA class I expression does not result from immunoediting but rather from an EMT process associated to myeloid immunosuppression that predicts dismal prognosis.
-
15 GSE295809 对25例非肌层浸润性膀胱癌(NMIBC)原发肿瘤样本进行mRNA表达谱分析,通过RNA测序检测其转录组特征,比较基于转录组的mRNA风险评分与传统EORTC风险评分在预测早期复发中的准确性。
设计对25例非肌层浸润性膀胱癌(NMIBC)原发肿瘤样本进行mRNA表达谱分析,通过RNA测序检测其转录组特征,比较基于转录组的mRNA风险评分与传统EORTC风险评分在预测早期复发中的准确性。
摘要Background Bladder cancer represents a heterogeneous disease with distinct clinical challenges. Non-muscle invasive bladder cancer (NMIBC) typically presents as indolent and slow-growing, yet a critical clinical challenge remains: identifying which patients will progress to muscle-invasive disease requiring radical interventions. Early detection of progression propensity is essential, as once muscle invasion occurs, the risk of distant metastasis increases substantially, and treatment shifts from conservative TURBT (Transurethral Resection of Bladder Tumor) to aggressive surgical interventions with significant morbidity. Current risk stratification methods fail to adequately predict this transition in approximately 30% of cases, highlighting the urgent need for more accurate prognostic tools. Objective This retrospective study aimed to develop and validate a transcriptomics-based mRNA score for predicting early NMIBC recurrence, comparing its performance against traditional risk stratification methods. Methods We analyzed mRNA expression profiles from primary retrospective NMIBC tumor specimens (n=25) collected between [2018-2022]. Traditional risk stratification tools, including EORTC scoring, were applied alongside our novel mRNA-based risk score to evaluate predictive accuracy for recurrence. Results The transcriptomics-based mRNA score demonstrated a median prediction accuracy of 90% across 10,000 resampling iterations for predicting early NMIBC recurrence, significantly outperforming traditional EORTC risk scores. Our comprehensive gene set identified 435 differentially expressed genes associated with recurrence. Kaplan-Meier analysis showed significantly different recurrence-free survival between high and low mRNA risk score groups (Bonferroni corrected p-value<0.0001). Conclusions This retrospective analysis confirms that mRNA expression-based risk stratification provides superior predictive accuracy compared to conventional clinicopathologic risk tools. Implementation of this gene signature could potentially reduce over-investigation and improve surveillance cost-effectiveness after TURBT in patients with primary high-risk NMIBC. These findings may transform the clinical management paradigm by enabling more personalized follow-up protocols based on molecular risk assessment.
-
16 GSE37815 对膀胱癌患者及正常组织样本进行DNA甲基化和基因表达微阵列分析,比较非肌层浸润性膀胱癌与正常组织的甲基化差异,并分析甲基化状态与基因表达水平及临床预后特征的关系。
设计对膀胱癌患者及正常组织样本进行DNA甲基化和基因表达微阵列分析,比较非肌层浸润性膀胱癌与正常组织的甲基化差异,并分析甲基化状态与基因表达水平及临床预后特征的关系。
摘要The DNA methylation patterns associated with the development and progression of cancer. The aim of the present study was to identify novel methylation markers that can discriminate between normal and Non-muscle-invasive bladder cancer (NMIBC), and between good and poor prognosis using microarray analysis of DNA methylation and RNA expression patterns in NMIBC patients. From the 24 matched microarray-based DNA methylation and gene expression profiling data set, tumor specific hypermethylated genes were selected and clinical relevance of these genes were verified by quantitative PQS analyses. Methylation statues of several genes were significantly associated with decreased gene expression levels and aggressive clinicopathological characteristics. In multivariate regression analyses, hypermethylation of these genes were the independent predictors of recurrence and progression.
-
17 GSE57813 对96例T1G3膀胱癌患者(排除合并CIS者)的FFPE组织样本进行回顾性分析,采集21例进展性与非进展性患者的基因表达数据,采用微阵列检测;另选取75例独立样本,通过定量PCR分析94个关键基因表达水平,比较两种分组间的差异。
设计对96例T1G3膀胱癌患者(排除合并CIS者)的FFPE组织样本进行回顾性分析,采集21例进展性与非进展性患者的基因表达数据,采用微阵列检测;另选取75例独立样本,通过定量PCR分析94个关键基因表达水平,比较两种分组间的差异。
摘要To analyze the gene expression profiles of progressive and non-progressive T1G3 bladder cancer (BCa) patients in order to develop a gene expression signature to predict tumour progression. Multicenter, retrospective study of formalin-fixed paraffin embedded (FFPE) tissue samples from 96 T1G3 BCa patients who underwent a transurethral resection. Patients with concomitant CIS were excluded. Global gene expression patterns were analyzed in 21 selected samples from progressive and non-progressive T1G3 BCa patients using microarrays. Expression levels of 94 key genes selected from microarrays and from the literature were studied by quantitative PCR in an independent cohort of 75 samples from progressive and non-progressive T1G3 BCa patients. Univariate logistic regression was used to identify individual predictors. Progressive and non-progressive T1G3 BCa patients show different gene expression patterns. Identification of new genes associated with a high probability of tumour progression in combination with a robust, easy-to-use and reliable algorithm may contribute to tailor treatment and surveillance strategies in these patients.
-
18 GSE27448 将膀胱癌样本与正常膀胱组织进行微阵列分析,比较差异表达基因。研究对象包括10例尿路上皮癌样本(按组织学分组)和5例正常组织样本,采用CodeLink 57k Human Whole Genome芯片检测,所有肿瘤样本与正常对照比较差异表达基因。
设计将膀胱癌样本与正常膀胱组织进行微阵列分析,比较差异表达基因。研究对象包括10例尿路上皮癌样本(按组织学分组)和5例正常组织样本,采用CodeLink 57k Human Whole Genome芯片检测,所有肿瘤样本与正常对照比较差异表达基因。
摘要Background: Current diagnosis and treatment of urinary bladder cancer (BC) has shown great progress with the utilization of microarrays. Purpose: Our goal was to identify common differentially expressed (DE) genes among clinically relevant subclasses of BC using microarrays. Methodology/Principal Findings: BC samples and controls, both experimental as well as publicly available datasets, were analyzed by whole genome microarrays. We grouped the samples according to their histology and defined the DE genes in each sample individually as well as in each tumor group, respectively. A dual analysis strategy was followed: First, experimental samples were analyzed and conclusions were extracted; and second, experimental sets were combined with publicly available microarray datasets and were further analyzed in search for common DE genes. The experimental dataset, identified 831 genes that were differentially expressed in all tumor samples, simultaneously. Moreover, 33 genes were up-regulated and 85 genes were down-regulated in all 10 BC samples compared to the 5 normal tissues, simultaneously. Hierarchical clustering partitioned tumor groups in accordance to their histology. K-means clustering of all genes and all samples, as well as clustering of tumor groups, presented 49 clusters. K-means clustering of common DE genes in all samples revealed 24 clusters. Genes manifested various differential patterns of expression, based on PCA. YY1 and NFκB were among the most common transcription factors that regulated the expression of the identified DE genes. Chromosome 1 contained 32 DE genes, followed by chromosomes 2 and 11, which contained 25 and 23 DE genes, respectively. Chromosome 21 had the least number of DE genes. GO analysis revealed the prevalence of transport and binding genes in the common down-regulated DE genes; the prevalence of RNA metabolism and processing genes in the up-regulated DE genes; as well as the prevalence of genes responsible for cell communication and signal transduction in the DE genes that were down-regulated in T1-Grade III tumors and up-regulated in T2/T3-Grade III tumors. Combination of all available samples revealed 17 common genes (BMP4, CRYGD, DBH, GJB1, KRT83, MPZ, NHLH1, TACR3, ACTC1, MFAP4, SPARCL1, TAGLN, TPM2, CDC20, LHCGR, TM9SF1 and HCCS) four of which participate in numerous pathways. Conclusions/Significance: The identification of the common DE genes among BC samples of different histology can provide further insight into the discovery of new putative markers.
人源·鼠源bulk 转录组
Human · Mouse · Bulk RNA-seq
-
01 GSE38264 对人类膀胱癌复发样本及非复发样本、小鼠正常膀胱组织及转基因膀胱肿瘤组织进行基因表达分析,比较不同基因型小鼠与人类样本在肿瘤复发状态下的转录组差异。
设计对人类膀胱癌复发样本及非复发样本、小鼠正常膀胱组织及转基因膀胱肿瘤组织进行基因表达分析,比较不同基因型小鼠与人类样本在肿瘤复发状态下的转录组差异。
摘要Bladder cancer (BC) is a highly prevalent human disease in which Rb pathway inactivation and epigenetic alterations are common events. However, the connection between these two processes is still poorly understood. Here we show that the in vivo inactivation of all Rb family genes in the mouse urothelium is sufficient to initiate BC development. The characterization of the mouse tumors revealed multiple molecular features of human BC, including the activation of E2F transcription factor and subsequent Ezh2 expression, and the activation of several signaling pathways previously identified as highly relevant in urothelial tumors. Whole transcriptional characterizations of the mouse bladder tumors revealed a significant overlap with human BC samples, and a predominant role for Ezh2 in the downregulation of gene expression programs. Importantly, we determined that in human superficial BC patients, the increased tumor recurrence and progression in these recurrences is associated with increased E2F and Ezh2 expression and Ezh2-mediated gene expression repression. Collectively, our studies provide a genetically defined model for human high-grade superficial BC and demonstrate the existence of an Rb-E2F-Ezh2 axis in bladder whose disruption can promote tumor development.

课题合作 · 扫码加微信
bioinformaticsboy